These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 20026142)

  • 1. Vasoactive intestinal peptide (VIP) receptor expression in monocyte-derived macrophages from COPD patients.
    Burian B; Storka A; Marzluf BA; Yen YC; Lambers C; Robibaro B; Vonbank K; Mosgoeller W; Petkov V
    Peptides; 2010 Apr; 31(4):603-8. PubMed ID: 20026142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pituitary adenylate cyclase-activating polypeptide and PACAP receptor expression and function in the rat adrenal gland.
    Mazzocchi G; Malendowicz LK; Neri G; Andreis PG; Ziolkowska A; Gottardo L; Nowak KW; Nussdorfer GG
    Int J Mol Med; 2002 Mar; 9(3):233-43. PubMed ID: 11836629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation.
    Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
    J Immunol; 1999 Apr; 162(8):4685-96. PubMed ID: 10202009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
    Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
    Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VIP attenuation of the severity of experimental pancreatitis is due to VPAC1 receptor-mediated inhibition of cytokine production.
    Kojima M; Ito T; Oono T; Hisano T; Igarashi H; Arita Y; Kawabe K; Coy DH; Jensen RT; Nawata H
    Pancreas; 2005 Jan; 30(1):62-70. PubMed ID: 15632701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin.
    Reubi JC; Läderach U; Waser B; Gebbers JO; Robberecht P; Laissue JA
    Cancer Res; 2000 Jun; 60(11):3105-12. PubMed ID: 10850463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VPAC1 (vasoactive intestinal peptide (VIP) receptor type 1) G protein-coupled receptor mediation of VIP enhancement of murine experimental colitis.
    Yadav M; Huang MC; Goetzl EJ
    Cell Immunol; 2011; 267(2):124-32. PubMed ID: 21295288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptors in normal and neoplastic human tissues with subtype-specific antibodies.
    Schulz S; Röcken C; Mawrin C; Weise W; Höllt V; Schulz S
    Clin Cancer Res; 2004 Dec; 10(24):8235-42. PubMed ID: 15623599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pituitary adenylate cyclase-activating peptide/vasoactive intestinal peptide receptors in human normal mammary gland and breast cancer tissue.
    García-Fernández MO; Collado B; Bodega G; Cortés J; Ruíz-Villaespesa A; Carmena MJ; Prieto JC
    Gynecol Endocrinol; 2005 Jun; 20(6):327-33. PubMed ID: 16019382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies.
    Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
    J Immunol; 1999 Feb; 162(3):1707-16. PubMed ID: 9973433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization and expression of different pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptors in rat ovarian follicles.
    Vaccari S; Latini S; Barberi M; Teti A; Stefanini M; Canipari R
    J Endocrinol; 2006 Oct; 191(1):287-99. PubMed ID: 17065411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Down-regulation of vasoactive intestinal peptide and altered expression of its receptors in rat diabetic cardiomyopathy.
    Dvoráková MC; Pfeil U; Kuncová J; Svíglerová J; Galvis G; Krasteva G; König P; Grau V; Slavíková J; Kummer W
    Cell Tissue Res; 2006 Mar; 323(3):383-93. PubMed ID: 16344947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of VPAC1 and VPAC2 in VIP mediated inhibition of rat pulmonary artery and aortic smooth muscle cell proliferation.
    St Hilaire RC; Murthy SN; Kadowitz PJ; Jeter JR
    Peptides; 2010 Aug; 31(8):1517-22. PubMed ID: 20452385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the role of the PAC1 receptor in neutrophil recruitment, acute-phase response, and nitric oxide production in septic shock.
    Martínez C; Juarranz Y; Abad C; Arranz A; Miguel BG; Rosignoli F; Leceta J; Gomariz RP
    J Leukoc Biol; 2005 May; 77(5):729-38. PubMed ID: 15661828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors (VPAC1, VPAC2, and PAC1 receptor) in the rat brain.
    Joo KM; Chung YH; Kim MK; Nam RH; Lee BL; Lee KH; Cha CI
    J Comp Neurol; 2004 Aug; 476(4):388-413. PubMed ID: 15282712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic association of vasoactive intestinal peptide receptor with rheumatoid arthritis: altered expression and signal in immune cells.
    Delgado M; Robledo G; Rueda B; Varela N; O'Valle F; Hernandez-Cortes P; Caro M; Orozco G; Gonzalez-Rey E; Martin J
    Arthritis Rheum; 2008 Apr; 58(4):1010-9. PubMed ID: 18383379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide stimulate interleukin-6 production in prostate cancer cells and prostatic epithelial cells.
    Nagakawa O; Junicho A; Akashi T; Koizumi K; Matsuda T; Fuse H; Saiki I
    Oncol Rep; 2005 Jun; 13(6):1217-21. PubMed ID: 15870945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered expression of vasoactive intestinal peptide receptors in T lymphocytes and aberrant Th1 immunity in multiple sclerosis.
    Sun W; Hong J; Zang YC; Liu X; Zhang JZ
    Int Immunol; 2006 Dec; 18(12):1691-700. PubMed ID: 17077178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toll-like receptor 2 expression is decreased on alveolar macrophages in cigarette smokers and COPD patients.
    Droemann D; Goldmann T; Tiedje T; Zabel P; Dalhoff K; Schaaf B
    Respir Res; 2005 Jul; 6(1):68. PubMed ID: 16004610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression of vasoactive intestinal peptide receptors in human lung cancer.
    Szilasi M; Buglyo A; Treszl A; Kiss L; Schally AV; Halmos G
    Int J Oncol; 2011 Oct; 39(4):1019-24. PubMed ID: 21769421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.